» Articles » PMID: 20085465

Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-infected Persons Without Hepatitis B or C Virus Co-infection

Overview
Journal Clin Infect Dis
Date 2010 Jan 21
PMID 20085465
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic liver disease in human immunodeficiency virus (HIV)-infected patients is mostly caused by hepatitis virus co-infection. Other reasons for chronic alanine aminotransferase (ALT) elevation are more difficult to diagnose.

Methods: We studied the incidence of and risk factors for chronic elevation of ALT levels (greater than the upper limit of normal at 2 consecutive semi-annual visits) in participants of the Swiss HIV Cohort Study without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection who were seen during the period 2002-2008. Poisson regression analysis was used.

Results: A total of 2365 participants were followed up for 9972 person-years (median age, 38 years; male sex, 66%; median CD4+ cell count, 426/microL; receipt of antiretroviral therapy [ART], 56%). A total of 385 participants (16%) developed chronic elevated ALT levels, with an incidence of 3.9 cases per 100 person-years (95% confidence interval [CI], 3.5-4.3 cases per 100 person-years). In multivariable analysis, chronic elevated ALT levels were associated with HIV RNA level >100,000 copies/mL (incidence rate ratio [IRR], 2.23; 95% CI, 1.45-3.43), increased body mass index (BMI, defined as weight in kilograms divided by the square of height in meters) (BMI of 25-29.9 was associated with an IRR of 1.56 [95% CI, 1.24-1.96]; a BMI 30 was associated with an IRR of 1.70 [95% CI, 1.16-2.51]), severe alcohol use (1.83 [1.19-2.80]), exposure to stavudine (IRR per year exposure, 1.12 [95% CI, 1.07-1.17]) and zidovudine (IRR per years of exposure, 1.04 [95% CI, 1.00-1.08]). Associations with cumulative exposure to combination ART, nucleoside reverse-transcriptase inhibitors, and unboosted protease inhibitors did not remain statistically significant after adjustment for exposure to stavudine. Black ethnicity was inversely correlated (IRR, 0.52 [95% CI, 0.33-0.82]). Treatment outcome and mortality did not differ between groups with and groups without elevated ALT levels.

Conclusions: Among patients without hepatitis virus co-infection, the incidence of chronic elevated ALT levels was 3.9 cases per 100 person-years, which was associated with high HIV RNA levels, increased BMI, severe alcohol use, and prolonged stavudine and zidovudine exposure. Long-term follow-up is needed to assess whether chronic elevation of ALT levels will result in increased morbidity or mortality.

Citing Articles

Liver function tests, CD4 counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study.

Mengistu E, Malik D, Molla M, Adugna A, Jemal M Heliyon. 2024; 10(12):e33054.

PMID: 38988551 PMC: 11234096. DOI: 10.1016/j.heliyon.2024.e33054.


Chronic Liver Enzyme Elevation and Use of Contemporary ARVs Among People With HIV.

Roen A, Peters L, Wandeler G, Van Der Valk M, Zangerle R, Gunthard H Open Forum Infect Dis. 2024; 11(6):ofae308.

PMID: 38919512 PMC: 11196901. DOI: 10.1093/ofid/ofae308.


Aspartate Aminotransferase/Platelet Ratio Index Upon Admission Predicts 24-Week Mortality in Patients With HIV-Associated .

Wang Q, Zhao H, Tong Y, Qin J, Zhou M, Xu L Open Forum Infect Dis. 2023; 10(12):ofad593.

PMID: 38107017 PMC: 10721445. DOI: 10.1093/ofid/ofad593.


Substance Use, Highly Active Antiretroviral Therapy, and Liver Enzymes: Evidence From a Cross-Sectional Study of HIV-Infected Adult Patients Without Comorbidities on HAART in the University of Port Harcourt Teaching Hospital.

Anyanwu C, JohnBull T, Usman I, Aigbogun Jr E, Ochai J, Qasem A Front Reprod Health. 2022; 3:664080.

PMID: 36303994 PMC: 9580740. DOI: 10.3389/frph.2021.664080.


Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.

Morsica G, Galli L, Messina E, Castagna A, Bagaglio S, Salpietro S PLoS One. 2022; 17(2):e0262917.

PMID: 35113890 PMC: 8812874. DOI: 10.1371/journal.pone.0262917.